EUVIMEDEUVIMED entdecken
Crossref

Factors Impacting Overall Survival Post‐Relapse in High‐Risk Neuroblastoma: Children's Oncology Group Outcomes From 2000 to 2019

Monica Davini, Arlene Naranjo iD, Lulu Chen, Rochelle Bagatell, Steven G DuBois iD, Meredith S Irwin, Kelly C Goldsmith, Michael D Hogarty, Katherine K Matthay iD

Pediatric Blood & Cancer · 2026

DOI: 10.1002/1545-5017.70520 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Monica Davini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Banner University Medical Center, University of Arizona Cancer Center, Tucson, Arizona, USA. Hauptthemen laut MEDLINE: Neuroblastoma, Neoplasm Recurrence, Local. Die Arbeit nennt 21 Literaturangaben. Gefördert von: National Cancer Institute of the National Institutes of Health, Children's Oncology Group, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Prior studies of features impacting post‐relapse survival in high‐risk neuroblastoma (HRNB) evaluated patient cohorts that did not receive contemporary high‐risk or relapse therapies. We describe overall survival (OS) after first progression or first relapse of HRNB in a modern cohort.

Methods

Patients with HRNB enrolled on COG ANBL00B1(NCT00904241) between 2000 and 2019, who had relapsed or progressive disease were eligible. Clinical and molecular risk factors at diagnosis, therapy era, clinical trial enrollment, and clinical features at relapse, including site of and time to relapse, were evaluated. OS post‐relapse was compared between groups using log‐rank tests and Cox models.

Results

Among 4253 eligible HRNB patients, 1616 had relapse or progression as a first event. Five‐year OS post‐relapse was 19.1 ± 1.1%. The risk group with the lowest post‐relapse survival was observed in patients with INSS Stage 4 or 4S disease < 18 months of age at diagnosis with MYCN amplified (MYCN‐A) tumors. The other significant most unfavorable factors at diagnosis included diagnosis 2000–2004, tumor MYCN‐A, 1p loss of heterozygosity (LOH), and elevated LDH or ferritin. Unfavorable factors at relapse included the time to relapse < 36 months from diagnosis, and combined local and metastatic disease at relapse. Multivariable analysis indicated that those with tumors harboring 1p LOH, age ≤ 5 years at diagnosis, or earlier treatment therapy era (2000–2004) had a higher risk of post‐relapse death.

Conclusions

While the 5‐year OS rate was low in this cohort, there are subsets of patients with relapsed HRNB who demonstrate long‐term survival. Trials Registration ClinicalTrials.gov identifier: NCT00904241

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaNeoplasm Recurrence, LocalHumansFemaleMaleInfantChild, PreschoolSurvival RateRisk FactorsPrognosisFollow-Up StudiesChild

Stichwörter der Autor:innen

high‐risk neuroblastomaprognostic factorsrelapse

Autor:innen und Institutionen

  • Banner University Medical Center, University of Arizona Cancer Center, Tucson, Arizona, USA.
  • University of Florida Children's Oncology Group Statistics & Data Center, Gainesville, Florida, USA.
  • Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, Canada.
  • Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, Georgia, USA.

ORCID-Profile: Arlene Naranjo, Steven G DuBois, Katherine K Matthay

Förderung

  • National Cancer Institute of the National Institutes of Health
  • Children's Oncology Group
  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Davini, M., Naranjo, A., Chen, L., Bagatell, R., DuBois, S. G., Irwin, M. S., Goldsmith, K. C., Hogarty, M. D., & Matthay, K. K. (2026). Factors Impacting Overall Survival Post‐Relapse in High‐Risk Neuroblastoma: Children's Oncology Group Outcomes From 2000 to 2019. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70520

Vancouver

Davini M, Naranjo A, Chen L, Bagatell R, DuBois SG, Irwin MS, et al. Factors Impacting Overall Survival Post‐Relapse in High‐Risk Neuroblastoma: Children's Oncology Group Outcomes From 2000 to 2019. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70520

BibTeX
@article{Davini2026,
  author = {Davini, Monica and Naranjo, Arlene and Chen, Lulu and Bagatell, Rochelle and DuBois, Steven G and Irwin, Meredith S and Goldsmith, Kelly C and Hogarty, Michael D and Matthay, Katherine K},
  title = {Factors Impacting Overall Survival Post‐Relapse in High‐Risk Neuroblastoma: Children's Oncology Group Outcomes From 2000 to 2019},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  doi = {10.1002/1545-5017.70520}
}
Kostenlos starten →